You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

Carl Heneghan

Better Decisions Require Research that Matters: Part 4

25 May, 16 | by BMJ Clinical Evidence

Carl Heneghan

 

by Carl Heneghan

This blog was originally written for Evidence Live blogs and posted on evidencelive.org

 

 

Poor quality evidence, lack of affordability and uninformed patients suggest an awful lot of research doesn’t actually matter. However, for informing better decisions when presented with a piece of evidence there are three questions that I use to identify and weed out most research that doesn’t matter: 1) does this research apply to my patient; 2) is the research of sufficient length to inform the outcome given the clinical course of the disease, and 3) will this evidence make a difference to my patient’s outcome? more…

Better Decisions Require Better Informed Patients: Part 3

25 May, 16 | by BMJ Clinical Evidence

Carl Heneghan

 

by Carl Heneghan

This blog was originally written for Evidence Live blogs and posted on evidencelive.org

 

 

The first two articles in this series pointed out we need better and more affordable evidence. Yet, even if affordable high quality evidence is forthcoming it is imperative that patients can make informed decisions and that doctors have the tools to actually inform patients it in practice.

There is, however, growing unease that the current system is not serving patients information needs. Sally Davies, the UK’s Chief Medical Officer (CMO), recently requested a review to restore public trust in the safety and effectiveness of medicines, because patients increasingly see doctors as over-medicating and clinical scientists who are afflicted by conflicts of interest: the CMO therefore considers it is difficult for the public to trust either. more…

Better Decisions Require More Affordable Treatments: Part 2

25 May, 16 | by BMJ Clinical Evidence

Carl Heneghanby Carl Heneghan

This blog was originally written for Evidence Live blogs and posted on evidencelive.org

Part 1 of this series pointed out we need better research to support better decisions. Market forces, though, may not be helping decision-making as new treatments – particularly drugs – are increasingly unaffordable and out of the reach of payers…

Estimates suggest the development of a newly approved drug currently costs around $2.6billion.  A high proportion of current costs are driven by high failure rates, the spiralling costs of clinical trials and competition with existing treatments that already have substantial effectiveness. As an example, Astra Zeneca’s five year drug development pipeline analysis reported only 2% of their products made it to market in this period: 59% of drugs completed Phase 1; only 15% completed Phase II, where most failures occurred and most improvement is required, and 60% completed Phase III. Whilst R&D costs have increased almost exponentially output has flatlined over the same time period. more…

Better Decisions Require Better Evidence: Part 1

25 May, 16 | by BMJ Clinical Evidence

Carl Heneghanby Carl Heneghan

The campaign starts at EvidenceLive 2016 – with  an open meeting to prioritise and explore the potential solutions to better evidence for better decisions.

This blog was originally written for Evidence Live blogs and posted on evidencelive.org

At the core of evidence-based medicine is the integration of patient values and high quality evidence. Informed patients should also understand their treatment options and actively participate in making decisions about their own health, and  to achieve this, clinicians require better research evidence. However, there are growing concerns that a sizeable amount of current published research is irrelevant, wasteful and detrimental to patient care. more…

BMJ Clinical Evidence Blog homepage

BMJ Clinical Evidence

Clinical Evidence is a database of systematic overviews on the effectiveness of key interventions, together with tools and resources to learn and practise EBM. Visit site



Creative Comms logo

BMJ Clinical Evidence latest news

BMJ Clinical Evidence latest news